Daily Archives: August 29, 2022 | LinksMedicus Free Medical News & Perspectives

#ESCCongress – RCT | In patients with severe ischemic left ventricular systolic dysfunction under optimal medical therapy, revascularization by PCI did not improve outcomes.

29 Aug, 2022 | 12:38h | UTC

Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Coronary stenting does not benefit patients with severe left ventricular dysfunction – European Society of Cardiology

Commentary: DANCAVAS: CV Screening Did Not Significantly Reduce Incidence of Death in Older Males – American College of Cardiology

Commentary on Twitter

REVIVED-BCIS2: In patients with a low left ventricular ejection fraction and viable myocardium, PCI did not reduce the incidence of death from any cause or hospitalization for heart failure. #ESCCongress https://t.co/XtZlkJ7GAf pic.twitter.com/6uMNemzkyN

— NEJM (@NEJM) August 27, 2022

#ESCCongress – Meta-analysis of randomized trials | SGLT-2 inhibitors in patients with heart failure.

29 Aug, 2022 | 12:35h | UTC

SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials – The Lancet (free registration required)

Commentary on Twitter

Our meta-analysis of SGLT2 inhibitors in HF is now online in @TheLancet showing a
consistent reduction in the risk of CV death and HF hospitalisation in a broad range of 21,947
patients across range of EF and in different care settingshttps://t.co/qnxgayR235 pic.twitter.com/x0RsINoE9y

— Kieran Docherty (@Kieranfdocherty) August 27, 2022

#ESCCongress – RCT | Dapagliflozin reduced the risk of worsening heart failure or cardiovascular death in patients with heart failure with mildly reduced or preserved ejection fraction.

29 Aug, 2022 | 12:36h | UTC

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Dapagliflozin benefits patients with mildly reduced and preserved ejection fraction – European Society of Cardiology

Commentary on Twitter

DELIVER: In an RCT involving patients with HF and a mildly reduced or preserved ejection fraction, dapagliflozin reduced the risk of the composite outcome of worsening heart failure or CV death. #ESCCongress https://t.co/0umSDn5HkO pic.twitter.com/nq7zD2Fi2K

— NEJM (@NEJM) August 27, 2022

#ESCCongress – RCT | In patients with rheumatic heart disease–associated atrial fibrillation, treatment with a Vitamin K antagonist led to a lower rate of cardiovascular events or death compared to Rivaroxaban.

29 Aug, 2022 | 12:33h | UTC

Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Trial backs standard of care for rheumatic heart disease and atrial fibrillation – European Society of Cardiology

Commentary: INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF – TCTMD

Commentary on Twitter

INVICTUS: In patients with RHD-associated AF, compared to rivaroxaban, VKA reduced cardiovascular events and mortality without increasing bleeding. #ESCCongress https://t.co/4C45LmmB5o pic.twitter.com/9n3OelzZvp

— NEJM (@NEJM) August 28, 2022

[News release – not published yet] #ESCCongres – RCT | Evening dosing of blood pressure medication not better than morning dosing.

29 Aug, 2022 | 12:30h | UTC

Evening dosing of blood pressure medication not better than morning dosing – European Society of Cardiology

#ESCCongress – RCT | Routine functional testing is not better than standard care in high-risk patients after percutaneous coronary intervention.

29 Aug, 2022 | 12:32h | UTC

Routine Functional Testing or Standard Care in High-Risk Patients after PCI – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary on Twitter

POST-PCI: In a randomized trial of patients who underwent percutaneous coronary intervention, routine stress testing did not improve clinical outcomes at two years. #ESCCongress https://t.co/nil00HQm4Z pic.twitter.com/o4v0UcDfYV

— NEJM (@NEJM) August 28, 2022

Bedtime dosing of antihypertensive medications: systematic review and consensus statement. – “use of bedtime drug dosing of antihypertensive drugs should not be routinely recommended”.

29 Aug, 2022 | 12:28h | UTC

Bedtime dosing of antihypertensive medications: systematic review and consensus statement: International Society of Hypertension position paper endorsed by World Hypertension League and European Society of Hypertension – Journal of Hypertension

RCT | Acetazolamide resulted in faster decongestion in patients with acute decompensated heart failure with volume overload.

29 Aug, 2022 | 12:25h | UTC

Acetazolamide in Acute Decompensated Heart Failure with Volume Overload – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Acetazolamide improves decongestion in patients with acute decompensated heart failure – European Society of Cardiology

Commentary: Acetazolamide in Decompensated Heart Failure With Volume Overload – ADVOR – American College of Cardiology

Commentary on Twitter

ADVOR: In a placebo-controlled trial, patients with acute decompensated heart failure and volume overload who had been randomly assigned to receive IV acetazolamide plus a loop diuretic had a higher incidence of decongestion. #ESCCongress https://t.co/YeoffDhXwc pic.twitter.com/YV3gM3gxij

— NEJM (@NEJM) August 27, 2022

#ESCCongress | In patients within 6 months of a myocardial infarction, a polypill containing aspirin, ramipril, and atorvastatin resulted in a lower risk of major adverse cardiovascular events compared to usual care.

29 Aug, 2022 | 12:27h | UTC

Polypill Strategy in Secondary Cardiovascular Prevention – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Polypill reduces cardiovascular events in heart attack patients compared to usual care – European Society of Cardiology

Commentaries:

SECURE: Treatment With Polypill Significantly Lowers Risk of Major CV Events – American College of Cardiology

Polypill Strategy Lowers Adverse CV Event Risk in Secondary Prevention – HCPLive

#ESCCongress | 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death.

29 Aug, 2022 | 12:21h | UTC

2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Developed by the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC) Endorsed by the Association for European Paediatric and Congenital Cardiology (AEPC) – European Heart Journal

News Release: People of all ages should learn cardiopulmonary resuscitation – European Society of Cardiology

#ESCCongress | 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery.

29 Aug, 2022 | 12:22h | UTC

2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery: Developed by the task force for cardiovascular assessment and management of patients undergoing non-cardiac surgery of the European Society of Cardiology (ESC) Endorsed by the European Society of Anaesthesiology and Intensive Care (ESAIC) – European Heart Journal

News Release: All patients over 65 years should have a heart check before high-risk non-cardiac surgery – European Society of Cardiology

#ESCCongress – RCT | A large study with 46.611 individuals between 65 and 74 years of age found that a comprehensive cardiovascular screening program did not significantly reduce the incidence of death from any cause.

29 Aug, 2022 | 12:24h | UTC

Five-Year Outcomes of the Danish Cardiovascular Screening (DANCAVAS) Trial – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Cardiovascular screening may reduce risk of death and cardiovascular disease – European Society of Cardiology

Commentary on Twitter

DANCANVAS: In men age 65-74 years in Denmark, those randomized to invitation to comprehensive screening for subclinical CVD did not have signif reduced all-cause mortality at median 5.6 yrs of follow-up. #ESCCongress https://t.co/YZL87aTVHR pic.twitter.com/HfdiNuU9sK

— NEJM (@NEJM) August 27, 2022

#ESCCongress | 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.

29 Aug, 2022 | 12:18h | UTC

2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG) – European Heart Journal

News Release: Pulmonary hypertension guidelines call for earlier diagnosis – European Society of Cardiology

#ESCCongress | 2022 ESC Guidelines on cardio-oncology.

29 Aug, 2022 | 12:17h | UTC

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC) – European Heart Journal – Cardiovascular Imaging

News Release: Advice to prevent heart problems caused by cancer therapy published today – European Society of Cardiology

Related guidelines:

Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations – Annals of Oncology

Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement from the American Heart Association – Circulation

Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline

Cardio-Onco-Hematology in Clinical Practice. Position Paper and Recommendations – Revista Espanola de Cardiologia

Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-Oncology—Part 1: acute coronary syndromes and acute pericardial diseases – European Heart Journal. Acute Cardiovascular Care

Brazilian Cardio-oncology Guideline – 2020 – Arquivos Brasileiros de Cardiologia

AHA Statement: Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors

#ESCCongress – RCT | In comatose survivors of out-of-hospital cardiac arrest, targeting a mean arterial blood pressure of 77 mmHg vs. 63 mmHg did not result in different outcomes.

29 Aug, 2022 | 12:13h | UTC

Blood-Pressure Targets in Comatose Survivors of Cardiac Arrest – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Trial finds no benefit of raising blood pressure target in post cardiac arrest patients – European Society of Cardiology

Commentary: Blood Pressure Targets Show No Benefit in Comatose Survivors of Cardiac Arrest – HCPLive

Commentary on Twitter

BOX BP: This randomized trial found no difference in the rate of death or severe disability/coma when patients following out-of-hospital cardiac arrest were managed with higher or lower blood pressure targets. #ESCCongress https://t.co/5qOMtiPSck pic.twitter.com/QOl5KetTvn

— NEJM (@NEJM) August 27, 2022

RCT | Cemiplimab plus chemotherapy vs. chemotherapy alone in non-small cell lung cancer.

29 Aug, 2022 | 12:08h | UTC

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial – Nature Medicine

Commentary on Twitter

Results from EMPOWER-Lung 3 demonstrate increased overall survival with #cemiplimab plus platinum-doublet #chemotherapy compared with cemiplimab as first-line treatment in patients with advanced non-small cell #LungCancer, irrespective of #PD-L1 expressionhttps://t.co/ojCDeivKzC

— Nature Medicine (@NatureMedicine) August 25, 2022

[News release – not published yet] #ESCCongress – RCT | Allopurinol does not improve cardiovascular outcomes in ischemic heart disease patients.

29 Aug, 2022 | 12:15h | UTC

Allopurinol does not improve cardiovascular outcomes in ischaemic heart disease patients – European Society of Cardiology

Commentary:

ALL-HEART: Gout Drug Allopurinol No Help in CV Prevention – TCTMD

No improvement with allopurinol for patients with ischemic heart disease: ALL-HEART – Cardiology Now

#ESCCongress – RCT | In comatose survivors of out-of-hospital cardiac arrest, a restrictive vs. a liberal oxygenation strategy resulted in similar incidences of death, severe disability, and coma.

29 Aug, 2022 | 12:12h | UTC

Oxygen Targets in Comatose Survivors of Cardiac Arrest – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Restrictive oxygenation in post cardiac arrest patients is not harmful – European Society of Cardiology

Commentary on Twitter

BOX Oxygen: This RCT found no difference in the rate of death or severe disability/coma when mechanically ventilated patients following out-of-hospital cardiac arrest were managed with higher or lower oxygenation targets. #ESCCongress https://t.co/qqtd4SyVrl pic.twitter.com/q73gqSuAn4

— NEJM (@NEJM) August 27, 2022

#ESCCongress – Single-arm study | Efficacy and safety of an extravascular implantable cardioverter–defibrillator.

29 Aug, 2022 | 12:09h | UTC

Efficacy and Safety of an Extravascular Implantable Cardioverter–Defibrillator – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary on Twitter

EV ICD: Extravascular ICD can be implanted safely and can detect and terminate induced ventricular arrhythmias at the time of implant. #ESCCongress https://t.co/Th9evkPcIu pic.twitter.com/qWEcM8MggT

— NEJM (@NEJM) August 28, 2022

Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK.

29 Aug, 2022 | 12:11h | UTC

Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK – The Lancet (free registration required)

Commentary: Population-based study: Autoimmune disorders increase risk of cardiovascular disease – MedicalXpress

Meta-analysis of randomized trials | Use of dexmedetomidine in patients with sepsis.

29 Aug, 2022 | 12:08h | UTC

Use of dexmedetomidine in patients with sepsis: a systematic review and meta-analysis of randomized-controlled trials – Annals of Intensive Care

M-A | Adverse pregnancy and birth outcomes associated with Mycoplasma hominis, Ureaplasma urealyticum and Ureaplasma parvum.

29 Aug, 2022 | 12:06h | UTC

Adverse pregnancy and birth outcomes associated with Mycoplasma hominis, Ureaplasma urealyticum and Ureaplasma parvum: a systematic review and meta-analysis – BMJ Open

Prevalence of multiple non-communicable diseases risk factors among adolescents in 140 countries: a population-based study.

29 Aug, 2022 | 12:04h | UTC

Prevalence of multiple non-communicable diseases risk factors among adolescents in 140 countries: A population-based study – eClinicalMedicine

Commentary on Twitter

Our study shows that a large proportion of adolescents in all countries are exposed to four or more NCD risk factors, irrespective of region. Insufficient vegetable and fruit consumption, sedentary behaviour and physical inactivity were most prevalent. https://t.co/NKz2VXTiYG pic.twitter.com/E0fM7h7fRz

— M Mamun Huda (@mmamunhuda) August 13, 2022